ROGERIO DE SOUZA

(Fonte: Lattes)
Índice h a partir de 2011
29
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Mostrar mais
Limpar filtros

Configurações

Colaboração internacional: Canadá × search.filters.applied.f.dateIssued: 2020 ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 22 Citação(ões) na Scopus
    Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents
    (2020) MCLAUGHLIN, Vallerie V.; CHANNICK, Richard; MARCO, Teresa De; FARBER, Harrison W.; GAINE, Sean; GALIE, Nazzareno; KRASUSKI, Richard A.; PRESTON, Ioana; SOUZA, Rogerio; COGHLAN, J. Gerry; FRANTZ, Robert P.; HEMNES, Anna; KIM, Nick H.; LANG, Irene M.; LANGLEBEN, David; LI, Mengtao; SITBON, Olivier; TAPSON, Victor; FROST, Adaani
    BACKGROUND: Treatment of pulmonary arterial hypertension (PAH) has evolved substantially over the past two decades and varies according to etiology, functional class (FC), hemodynamic parameters, and other clinical factors. Current guidelines do not provide definitive recommendations regarding the use of oral prostacyclin pathway agents (PPAs) in PAH. To provide guidance on the use of these agents, an expert panel was convened to develop consensus statements for the initiation of oral PPAs in adults with PAH. METHODS: A systematic literature search was conducted using MEDLINE. The established RAND/University of California Los Angeles appropriateness method, which incorporates the Delphi method and the nominal group technique, was used to create consensus statements. Idiopathic, heritable, repaired congenital heart defect, and drug- or toxin-induced PAH (IPAH+) was considered as one etiologic grouping. The process was focused on the use of oral treprostinil or selexipag in patients with IPAH+ or connective tissue disease-associated PAH and FC II or III symptoms receiving background dual endothelin receptor antagonist/phosphodiesterase type 5 inhibitor therapy. RESULTS: The panel developed 14 consensus statements regarding the appropriate use of oral PPAs in the target population. The panel identified 13 clinical scenarios in which selexipag may be considered as a treatment option. CONCLUSION: The paucity of clinical evidence overall, and particularly from randomized trials in this setting, creates a gap in knowledge. These consensus statements are intended to aid physicians in navigating treatment options and using oral PPAs in the most appropriate manner in patients with PAH.